Multicentre evaluation of the new ETEST gradient diffusion method for piperacillin-tazobactam susceptibility testing of Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii complex.
Piperacillin-tazobactam (P/T) is a β-lactam-β-lactamase inhibitor combination frequently used in the hospital setting. ETEST is a gradient diffusion method that represents an alternative to broth microdilution (BMD) for performing antimicrobial susceptibility testing. We conducted a multicentre evaluation of the performance of the new ETEST P/T compared to BMD following FDA and ISO 20776-2 criteria using FDA/CLSI and EUCAST interpretive breakpoints, respectively. A total of 977 isolates (775 Enterobacterales, 119 Pseudomonas aeruginosa and 83 Acinetobacter baumannii complex) were tested. Overall essential egreement (EA) ranged from 96.4% to 96.6% for Enterobacterales when following FDA and ISO 20776-2 criteria, respectively. EA yielded 98.3% for P. aeruginosa and 91.6% for A. baumannii complex for both FDA and ISO criteria. Applying FDA/CLSI breakpoints, categorical agreement (CA) reached 93.0%, 93.3% and 89.2% for Enterobacterales, P. aeruginosa and A. baumannii complex, respectively. Two very major errors (VME, 1.1%) were found among Enterobacterales (for 2 Klebsiella pneumoniae). No additional major errors (ME) or VMEs were found. Applying EUCAST breakpoints, CA yielded 94.8% and 95.8% for Enterobacterales and P. aeruginosa, respectively (no breakpoints are currently available for A. baumannii complex). No VMEs were observed among Enterobacterales but 2 (0.4%) MEs were found. Among P. aeruginosa, 2 (6.9%) VMEs and 3 (3.3%) MEs were observed. These errors resulted when ETEST P/T MICs were one doubling dilution apart from BMD. In conclusion, new ETEST P/T represents an accurate tool for performing antimicrobial susceptibility in Enterobacterales, P. aeruginosa and A. baumannii complex isolates with limited category errors.